[26] Y. Yigzaw, R. Piper, M. Tran, and A. A. Shukla, “Exploitation of the adsorptive

properties of depth filters for host cell protein removal during monoclonal antibody

purification,” Biotechnol. Prog., vol. 22, no. 1, pp. 288–296, 2006.

[27] M. Mellado and C. Peixoto, “Clarification of Adenovirus serotype 5: Robust pro-

tection of downstream purification steps application note,” 2017.

[28] T. P. Pato et al., “Development of a membrane adsorber based capture step for the

purification of yellow fever virus,” Vaccine, vol. 32, no. 24, pp. 2789–2793, 2014.

[29] T. Rodrigues, M. J. T. Carrondo, P. M. Alves, and P. E. Cruz, “Purification of

retroviral vectors for clinical application: Biological implications and technological

challenges,” J. Biotechnol., vol. 127, no. 3, pp. 520–541, Jan. 2007.

[30] S. B. Carvalho et al., “Efficient filtration strategies for the clarification of influenza

virus-like particles derived from insect cells,” Sep. Purif. Technol., vol. 218,

pp. 81–88, 2019.

[31] A. Xenopoulos, “Production and purification of hepatitis C virus-like particles

[Webinar]. EMD Millipore Webinar Series,” 2015.

[32] B. Kalbfuss, Y. Genzel, M. Wolff, A. Zimmermann, R. Morenweiser, and U.

Reichl, “Harvesting and concentration of human influenza A virus produced in

serum-free Mammalian cell culture for the production of vaccines,” Biotechnol.

Bioeng., vol. 97, no. 1, pp. 73–85, 2007.

[33] C. C. Liu et al., “Purification and characterization of enterovirus 71 viral particles

produced from vero cells grown in a serum-free microcarrier bioreactor system,”

PLoS One, vol. 6, no. 5, Article no. e20005, 2011.

[34] B. Zhang et al., “Immunogenicity of a scalable inactivated rotavirus vaccine in

mice,” Hum. Vaccin., vol. 7, no. 2, pp. 248–257, Feb. 2011.

[35] Y. E. Thomassen et al., “Scale-down of the inactivated polio vaccine production

process,” Biotechnol. Bioeng., vol. 110, no. 5, pp. 1354–1365, 2013.

[36] K. Trabelsi, M. Ben Zakour, and H. Kallel, “Purification of rabies virus produced in

Vero cells grown in serum free medium,” Vaccine, vol. 37, no. 47, pp. 7052–7060,

2019.

[37] R. J. S. Silva et al., “A flow – Through chromatographic strategy for hepatitis C

virus – Like particles purification,”Processes, vol. 8, pp. 1–13, 2020.

[38] Y. Cherradi, S. L. Merdy, L.-J.- Sim, T. Ito, P. Pattnaik, J. Haas , and A.

Boumlic , BioProcess Int. “Filter-based clarification of viral vaccines and vectors,”

vol. 16, no. 4, 2018.

[39] J. Vellinga et al., “Challenges in manufacturing adenoviral vectors for global

vaccine product deployment,” Hum. Gene Ther., vol. 25, no. 4, pp. 318–327, 2014.

[40] Y. Genzel et al., “High cell density cultivations by alternating tangential flow (ATF)

perfusion for influenza A virus production using suspension cells,” Vaccine, vol. 32,

no. 24, pp. 2770–2781, 2014.

[41] D. Vázquez-Ramírez, I. Jordan, V. Sandig, Y. Genzel, and U. Reichl, “High titer

MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy

with an ATF system,” Appl. Microbiol. Biotechnol., vol. 103, no. 7, pp. 3025–3035,

2019.

[42] B. Minow, F. Egner, F. Jonas, and B. Lagrange, “High-cell-density clarification by

single-use diatomaceous earth filtration,” BioProcess Int, vol. 12, no. 4, 2014.

[43] T. Williams et al., “Lentiviral vector manufacturing process enhancement utilizing

TFDF^TM technology,” Cell Gene Ther. Insights, vol. 6, no. 3, pp. 455–467, 2020.

[44] J. O. Konz, A. L. Lee, J. A. Lewis, and S. L. Sagar, “Development of a purification

process for adenovirus: Controlling virus aggregation to improve the clearance of

host cell DNA,” Biotechnol. Prog., vol. 21, no. 2, pp. 466–472, 2005.

[45] A. Ward, “Exploring a New Enzymatic Tool for AAV Production,” Genet. Eng.

Biotechnol. News, vol. 38, no. 3, 2018.

Downstream processing

197